Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A." POTTER-10
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 29 Jul 2017
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms POTTER 10
- Sponsors Bayer
- 24 Jul 2017 Planned End Date changed from 30 Jun 2017 to 30 Jul 2017.
- 24 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated